Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05550142
Other study ID # LVRNA012-IIT-02
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date September 16, 2022
Est. completion date March 2024

Study information

Verified date September 2022
Source AIM Vaccine Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a preliminary exploratory cohort study to evaluate safety, tolerability and immunogenicity of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine (LVRNA012) in participants aged 18 years and over in China.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 54
Est. completion date March 2024
Est. primary completion date December 19, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age at the time of first dose of vaccine: adults aged 18-59 years (including boundary values), elderly =60 years, both sexes; - Armpit temperature <37.3? on the day of enrollment; - Based on the medical history and relevant physical examination and laboratory examination results, the investigator clinically determined that the patient was in good health; - Subjects have independent judgment ability, can read, understand and complete vaccination diary cards, and they participate voluntarily and sign an informed consent form. Exclusion Criteria: - The subject has a history of SARS-CoV-2 or SARS infection, or has a history of contact with SARS-CoV-2 infected persons (nucleic acid test positive) or suspected infected persons within 30 days before screening, or living abroad within 30 days before screening history, or a positive SARS-CoV-2 nucleic acid test or a positive SARS-CoV-2 IgM or IgG test before the first dose of vaccine; - History of allergy to any component of the study vaccine or a history of a severe allergic reaction to the vaccine or drug (including but not limited to anaphylactic shock, anaphylactic laryngeal edema, anaphylactic purpura, thrombocytopenic purpura, or local anaphylactic necrosis [Arthus reaction]); - Upon questioning, have a history of COVID-19 vaccination, or have received other inactivated vaccines within 14 days before screening, and received live attenuated vaccines within 28 days; - Patients have a medical history or family history of epilepsy, convulsions, neurological diseases and mental diseases; - There are contraindications for intramuscular injection, such as: thrombocytopenia that has been diagnosed, any coagulation disorder or receiving anticoagulant treatment, etc.; - The investigator judges that he is known or suspected of having more serious diseases at the same time, including but not limited to: respiratory diseases (tuberculosis, lung failure, etc.), liver and kidney diseases, cardiovascular diseases (heart failure, severe hypertension, etc.), Malignant tumor, infection or allergic skin disease, HIV infection (test report can be provided), or during the active period of acute infection or chronic disease (within 3 days before vaccination); - Congenital malformations, developmental disorders, or chronic diseases that the investigator judges are not suitable for participating in this study (such as Downs syndrome, sickle cell anemia or neurological disorders, Guillain-Barre syndrome, etc.), excluding stable diabetes/hypertension ); - Patients with known immunological impairment or low immunological function diagnosed by the hospital before enrollment, or functional asplenia or splenectomy caused by any situation; - Those with evidence of tobacco, alcohol, and drug abuse, and those who did not agree to abstain from smoking and drinking during the study period; - During the screening period, laboratory tests (blood routine, urine routine, blood biochemistry, troponin, coagulation routine, D-dimer) and electrocardiogram abnormalities were clinically significant; - Female: those who have a positive blood pregnancy test, are pregnant, breastfeeding, or have a pregnancy plan within one year; men: whose spouse has a pregnancy plan within one year; - Patients have participated in other clinical trials (drugs, biological products or devices) within 3 months before the first dose of vaccine, or plan to participate in other clinical trials during the research period; - Patients received immune enhancement or immunosuppressive therapy within 6 months before the first dose of vaccine (continuous oral or instillation for more than 14 days); - Patients donated blood =400 ml within 28 days before screening, or received whole blood, plasma and immunoglobulin therapy within 6 months before screening; - Currently receiving research drug treatment to prevent COVID-19; - Patients are taking antipyretic, analgesic and anti-allergic drugs within 3 days before enrollment; - The investigator judges that the subjects cannot follow the research procedures, comply with the agreement, or plan to permanently relocate from the area before the end of the research, or plan to leave the local area for a long time during the scheduled visit period; - The relevant staff involved in this study or their immediate family members (such as spouses, parents, siblings or children); - According to the investigator's judgment, there are other situations that are not suitable for participating in this clinical trial.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine Low dose
50µg/dose
SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine High dose
100µg/dose
Drug:
Placebo
Saline solution

Locations

Country Name City State
China First Affiliated Hospital Bengbu Medical College Bengbu Anhui

Sponsors (3)

Lead Sponsor Collaborator
AIM Vaccine Co., Ltd. First Affiliated Hospital Bengbu Medical College, Ningbo Rongan Biological Pharmaceutical Co. Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other The positive conversion rate of S-protein specific antibody (IgG) against Novel coronavirus 2019 14 and 28 days after the first dose and 7, 14, 28 days, and 3, 6, and 12 months after the full course of vaccination
Other The geometric mean titers (GMT) of S protein-specific antibody (IgG) against Novel coronavirus 2019 14 and 28 days after the first dose and 7, 14, 28 days, and 3, 6, and 12 months after the full course of vaccination
Other The average growth fold compared with the baseline before exemption of S protein-specific antibody (IgG) against Novel coronavirus 2019 14 and 28 days after the first dose and 7, 14, 28 days, and 3, 6, and 12 months after the full course of vaccination
Other The positive conversion rate of anti-Novel coronavirus 2019 (Omicron BA.2, BA.4, BA.5 and Delta strains) true virus neutralizing antibodies 14 and 28 days after the first dose and 7, 14, 28 days, and 3, 6, and 12 months after the full course of vaccination
Other The positive conversion rate of anti-Novel coronavirus 2019 (Omicron BA.2, BA.4, BA.5 and Delta strains) pseudovirus neutralizing antibodies 14 and 28 days after the first dose and 7, 14, 28 days, and 3, 6, and 12 months after the full course of vaccination
Other The geometric mean titers (GMT) of anti-Novel coronavirus 2019 (Omicron BA.2, BA.4, BA.5 and Delta strains) true virus neutralizing antibodies 14 and 28 days after the first dose and 7, 14, 28 days, and 3, 6, and 12 months after the full course of vaccination
Other The average growth fold compared with the baseline before exemption of anti-Novel coronavirus 2019 (Omicron BA.2, BA.4, BA.5 and Delta strains) true virus neutralizing antibodies 14 and 28 days after the first dose and 7, 14, 28 days, and 3, 6, and 12 months after the full course of vaccination
Other The geometric mean titers (GMT) of anti-Novel coronavirus 2019 (Omicron BA.2, BA.4, BA.5 and Delta strains) pseudovirus neutralizing antibodies 14 and 28 days after the first dose and 7, 14, 28 days, and 3, 6, and 12 months after the full course of vaccination
Other The average growth fold compared with the baseline before exemption of anti-Novel coronavirus 2019 (Omicron BA.2, BA.4, BA.5 and Delta strains) pseudovirus neutralizing antibodies 14 and 28 days after the first dose and 7, 14, 28 days, and 3, 6, and 12 months after the full course of vaccination
Other Cellular immune responses against Novel Coronavirus 2019 (IL-2) 14, 28 days after the first dose and 7, 14, and 28 days after complete vaccination
Other Cellular immune responses against Novel Coronavirus 2019 (IL-4) 14, 28 days after the first dose and 7, 14, and 28 days after complete vaccination
Other Cellular immune responses against Novel Coronavirus 2019 (IL-13) 14, 28 days after the first dose and 7, 14, and 28 days after complete vaccination
Other Cellular immune responses against Novel Coronavirus 2019 (IL-?) 14, 28 days after the first dose and 7, 14, and 28 days after complete vaccination
Primary Incidence of solicited adverse events Within 28 days after each dose/full dose
Primary Incidence of unsolicited adverse events Within 28 days after each dose/full dose
Primary Incidence of adverse events associated with the study vaccine Within 28 days after each dose/full dose
Secondary Incidence of grade =3 adverse events Adverse events were graded from pain, tenderness, itching, induration, swelling and other aspects, and the higher the grade, the more serious the adverse events were Within 28 days after each dose/full dose
Secondary Incidence of grade =3 adverse events associated with the study vaccine Adverse events were graded from pain, tenderness, itching, induration, swelling and other aspects, and the higher the grade, the more serious the adverse events were Within 28 days after each dose/full dose
Secondary Statistics of withdrawal from the study due to adverse events Within 28 days after each dose/full dose
Secondary Incidence of SAE Within 28 days, 3 months, 6 months, and 12 months after the first dose of immunization to full immunization
Secondary Incidence of AESI Within 28 days, 3 months, 6 months, and 12 months after the first dose of immunization to full immunization
Secondary Incidence of SAE associated with the study vaccine Within 28 days, 3 months, 6 months, and 12 months after the first dose of immunization to full immunization
Secondary Incidence of AESI associated with the study vaccine Within 28 days, 3 months, 6 months, and 12 months after the first dose of immunization to full immunization
Secondary Incidence of clinically significant abnormalities in laboratory measures Through study completion, an average of 12 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT04527471 - Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19 Phase 2
Recruiting NCT05584202 - Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants Phase 2
Completed NCT04579549 - Repeat Testing for SARS-CoV-2 N/A
Active, not recruiting NCT05547243 - A Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants in China N/A
Recruiting NCT04747574 - Evaluation of the Safety of CD24-Exosomes in Patients With COVID-19 Infection Phase 1
Recruiting NCT04613310 - PCR and Rapid Diagnostic Test on Saliva and Nasopharyngeal Swabs for the Detection of SARS-CoV-2 (COVID-19) N/A
Terminated NCT04447404 - DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury Phase 2
Completed NCT04515147 - A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19 Phase 2
Withdrawn NCT04388709 - Interferon Lambda Therapy for COVID-19 Phase 2
Completed NCT04620798 - Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students N/A
Active, not recruiting NCT05547256 - A Preliminary Exploratory Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants Aged 18 Years and Over in China N/A
Completed NCT04561102 - Evaluation of the COVIDSeq Test in Nasal Swab and Saliva From a COVID-19 Asymptomatic Population
Completed NCT04452604 - Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19
Completed NCT05366322 - A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults
Terminated NCT04958304 - Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study
Completed NCT04526769 - Detecting SARS-CoV-2 in Tears
Completed NCT04690413 - NOWDx Test for the Detection of Antibodies to COVID-19 N/A
Active, not recruiting NCT05939648 - A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) Phase 2